CTRI/2020/11/029059
Recruiting
未知
TO STUDY ASSOCIATION OF BLOOD GLUCOSE CONTROL AND OUTCOME OF COVID 19 ILLNESS IN DIABETIC PATIENTS
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Sponsor
- A
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Inpatients in General Medicine with diagnosis of COVID 19 infection (Laboratory confirmed)
- •2\. Patients with pre existing diabetes or New onset diabetic patients.
Exclusion Criteria
- •1\. AGE Less than 18 YEARS
- •2\. Acute Myocardial infarction
- •3\. Acute cerebral vascular stroke
- •4\. Pregnant Female
- •5\. Impaired glucose tolerance
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of the link between blood glucose levels and neurocardiogenic syncope in adults who experience fainting episodes.eurocardiogenic syncopeHypoglycemiaNeurocardiogenic syncopeCardiovascular - Other cardiovascular diseasesMetabolic and Endocrine - Metabolic disordersNeurological - Other neurological disordersACTRN12616000431426Dr Angas Hamer50
Completed
Not Applicable
Study on the variables related to blood glucose control and safety of long-term ingestion of sterile packaged cooked rice.Healthy volunteersJPRN-UMIN000030710iigata Bio-Research Park , Inc36
Completed
Not Applicable
An observational study for blood glucose and lifestyle/habits SBF-2019-04ot applicableJPRN-UMIN000037674Suntory Beverage & Food Limited1,000
Completed
Not Applicable
An observational study for blood glucose and lifestyle/habits SBF-2019-05ot applicableJPRN-UMIN000038506Suntory Beverage & Food Limited93
Recruiting
Not Applicable
Comparative study for glycemic control and adherence when adding DPP-4 inhibitor alogliptin to patients with type 2 diabetes who had been treated with three times administration of alpha-glucosidase inhibitors but still in poor glycemic control by maintaining, reducing, or stopping the administration of alpha-glucosidase inhibitors.Type 2 DiabetesJPRN-UMIN000004259Graduate School of Medicine, Yokohama City University120